Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
West Virginia Univ. MAO-B compound 37
- Development stage
- Unknown
- Lead developer
- West Virginia University
01
Overview
West Virginia Univ. MAO-B compound 37: sourced facts only. name: "Two of the compounds, 37 and 57, displayed improved MAO-B potency and selectivity from MAO-A, with IC50 values of 270 and 460 nM respectively." [PMID:39631473]; target: "Two of the compounds, 37 and 57, displayed improved MAO-B potency and selectivity from MAO-A, with IC50 values of 270 and 460 nM respectively." [PMID:39631473]; developer: "Department of Chemistry, West Virginia University, Morgantown WV 26505, USA." [PMID:39631473]
02
Targets
MAOB (Monoamine oxidase B)
Beyond the preview
Go deeper on West Virginia Univ. MAO-B compound 37.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on West Virginia Univ. MAO-B compound 37.